drugset / Trial / NCT07599813
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
Timeline
- Start
- 2026-05-28
- Primary completion
- 2027-10-31
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camoteskimab | Monoclonal antibody | — | Subcutaneous |